Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

May 18, 2006 09:01 ET

Holmes Herbs, Inc.: Joint Marketing Agreement

SCOTTSDALE, ARIZONA--(CCNMatthews - May 18, 2006) - Holmes Herbs, Inc. (OTCBB:HMHB) announces that its clinical research subsidiary, Qualia Clinical Service, Inc. ("Qualia") has entered into a Joint Marketing Agreement (the "Agreement") with eResearchttTechnology, Inc. ("eRT").

The Agreement provides a framework through which both Qualia and eRT will work cooperatively to market each company's services to pharmaceutical and biotechnology clients. Both Qualia and eRT believe that by working together on selected clinical research studies, they will be better suited to provide comprehensive services to the sponsors. Mr. Robert Brown, Senior Vice-President of eRT, states, "Qualia has assembled a highly-capable team of seasoned professionals to conduct cardiac safety and other studies and to perform a variety of research services. We are pleased to be associated with Qualia during this exciting time in their company's development."

Dr. Sohail Khattak, President and CEO of Qualia, states, "eRT provides services that are complimentary to our clinical drug research. They are an established company with an excellent management team."

About Holmes and Qualia

Holmes Herbs Inc. (OTCBB:HMHB) recently entered into the clinical drug research business through its operating subsidiary, Qualia. It now has research facilities in Omaha, Nebraska and Toronto, Canada. Holmes is in the process of completing a name change to Holmes Biopharma, and a three for one stock split of its common shares. Following these corporate developments the company intends to enter into the drug development business.

About eRT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

On behalf of the Board of Directors

John F. Metcalfe, President and CEO

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information